- New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents.
- Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion.
- Additional data highlights synergistic activities between Trogarzo and dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational antiretroviral therapy (ARV).
Unitil Q2 EPS $0.30 Beats $0.23 Estimate
Unitil (NYSE:UTL) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.23 by 30.43 percent. This is a 66.67 percent increase over earnings of $0.18 per share from the same period
